Biophytis, US09076G1040

Biophytis, US09076G1040

22.12.2021 - 23:04:25

Biophytis announces the drawing of the last tranche of ORNANE under the 2020 Atlas Contract for ?3 million

Impact on a shareholder's 1% stake in the Company's capital prior to the transaction

Non diluted

Diluted

Before issuing of new ORNANE

?

Upon conversion of the ORNANE from 8 of Atlas: issuing of 6?410 256 additional shares

1.00?%

?

0.95?%

0.94?%

?

0.90?%

?

?

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information visit www.biophytis.com

?

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2021 Half Year Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

?

?

Biophytis Contact for Investor Relations

Evelyne Nguyen, CFO

Investors@biophytis.com

?

Media Contacts

Antoine Denry?:?antoine.denry@taddeo.fr?- +33 6 18 07 83 27Agathe Boggio?:?agathe.boggio@taddeo.fr?-?+33 7 62 77 69 42

?

Dissemination of a Financial Wire News, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.

Language: English Issuer: Biophytis 14 avenue de l'Op?ra 75001 Paris

France Internet: https://www.biophytis.com ISIN: US09076G1040, FR0012816825 EQS News ID: 1261421 ? End of Announcement - EQS News Service

1261421??22-Dec-2021?CET/CEST

@ dgap.de